Viewing Study NCT00944034

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 2:23 AM

Ignite Modification Date: 2025-12-28 @ 12:07 AM

Study NCT ID: NCT00944034

Status: COMPLETED

Last Update Posted: 2017-08-14

First Post: 2009-07-21

Is NOT Gene Therapy: True

Has Adverse Events: True

Brief Title: Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

Sponsor: Novartis Vaccines

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module Adverse Events Module Baseline Characteristics Module Participant Flow Module